Axsome TherapeuticsAXSM
AXSM
About: Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Employees: 589
0
Funds holding %
of 7,312 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
210% more first-time investments, than exits
New positions opened: 90 | Existing positions closed: 29
37% more capital invested
Capital invested by funds: $3.15B [Q4 2024] → $4.32B (+$1.17B) [Q1 2025]
28% more call options, than puts
Call options by funds: $111M | Put options by funds: $86.5M
20% more funds holding
Funds holding: 290 [Q4 2024] → 348 (+58) [Q1 2025]
9% more funds holding in top 10
Funds holding in top 10: 11 [Q4 2024] → 12 (+1) [Q1 2025]
0.85% less ownership
Funds ownership: 76.71% [Q4 2024] → 75.86% (-0.85%) [Q1 2025]
11% less repeat investments, than reductions
Existing positions increased: 101 | Existing positions reduced: 114
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$150
38%
upside
Avg. target
$174
60%
upside
High target
$190
74%
upside
7 analyst ratings
7 positive
100%
0 neutral
0%
0 negative
0%
Morgan Stanley Sean Laaman | 74%upside $190 | Overweight Assumed | 3 Jul 2025 |
RBC Capital Leonid Timashev | 71%upside $186 | Outperform Maintained | 12 Jun 2025 |
HC Wainwright & Co. Raghuram Selvaraju | 65%upside $180 | Buy Reiterated | 10 Jun 2025 |
Needham Ami Fadia | 38%upside $150 | Buy Maintained | 9 Jun 2025 |
Oppenheimer Matthew Hershenhorn | 70%upside $185 | Outperform Initiated | 3 Jun 2025 |
Financial journalist opinion
Based on 3 articles about AXSM published over the past 30 days
Neutral
GlobeNewsWire
2 days ago
Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4
NEW YORK, July 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the second quarter of 2025 on Monday, August 4, 2025, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update.
Neutral
GlobeNewsWire
4 days ago
Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21
NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will host its Frontiers in Brain Health R&D Day on July 21, 2025, starting at 11:00 a.m. Eastern Time in New York City. The event will highlight Axsome's singular, innovative late-stage CNS pipeline.
Neutral
GlobeNewsWire
3 weeks ago
Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month
NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today is joining with the Alzheimer's disease advocacy community to raise awareness of the growing impact of Alzheimer's disease in the United States and the importance of brain health during this year's Alzheimer's & Brain Awareness Month.
Neutral
GlobeNewsWire
1 month ago
Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025
NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced seven presentations, including two featured oral plenary sessions, on AXS-12 and solriamfetol, at SLEEP 2025, the 39th annual meeting of the Associated Professional Sleep Societies (APSS), being held June 8-11, 2025, in Seattle, Washington.
Positive
The Motley Fool
1 month ago
2 Soaring Stocks Wth More Upside Potential
Although fundamental investing wisdom tells us to "buy low," it may still be worthwhile to purchase shares of top companies following significant runs. Any point can be considered low -- even after massive gains -- provided there is plenty of upside left.
Negative
Zacks Investment Research
1 month ago
Why Is Axsome (AXSM) Down 1.8% Since Last Earnings Report?
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
Neutral
GlobeNewsWire
1 month ago
Axsome Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in three upcoming investor conferences in June:
Neutral
GlobeNewsWire
1 month ago
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd.
NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into a settlement agreement with Hetero Labs Ltd. and certain of its affiliates (Hetero) resolving patent litigation related to Axsome's product SUNOSI® (solriamfetol). The litigation, which is pending in the United States District Court for the District of New Jersey, resulted from submission by Hetero of an Abbreviated New Drug Application to the U.S. Food and Drug Administration seeking approval to market a generic version of SUNOSI in the United States. Under the terms of the settlement agreement, Axsome will grant Hetero a license to sell its generic version of SUNOSI beginning on or after September 1, 2040, if pediatric exclusivity is granted for SUNOSI, or on or after March 1, 2040, if no pediatric exclusivity is granted, subject to FDA approval and conditions and exceptions customary for agreements of this type.
Positive
The Motley Fool
1 month ago
3 High-Flying Stocks That Could Soar Even More
Many investors love the "big mo." That's short for "big momentum.
Positive
The Motley Fool
1 month ago
Is Axsome Therapeutics Stock Worth the Risk? A Comprehensive Analysis
Explore the exciting world of Axsome Therapeutics (AXSM -1.70%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
Charts implemented using Lightweight Charts™